BioNTech (NASDAQ:BNTX) CEO Sells $3,347,980.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 34,000 shares of the company’s stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $98.47, for a total transaction of $3,347,980.00. Following the sale, the chief executive officer directly owned 280,209 shares in the company, valued at approximately $27,592,180.23. The trade was a 10.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total transaction of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total value of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The stock was sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total value of $4,077,450.00.

BioNTech Stock Up 0.6%

BNTX stock traded up $0.56 during mid-day trading on Monday, reaching $99.08. The company had a trading volume of 777,945 shares, compared to its average volume of 1,094,445. The firm has a fifty day simple moving average of $98.17 and a 200 day simple moving average of $94.74. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The company has a market capitalization of $25.06 billion, a price-to-earnings ratio of -12.65 and a beta of 1.29. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. During the same period in the prior year, the firm posted ($1.60) earnings per share. The business’s quarterly revenue was down 59.5% compared to the same quarter last year. Analysts forecast that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several hedge funds have recently made changes to their positions in BNTX. Flossbach Von Storch SE acquired a new stake in shares of BioNTech during the second quarter worth about $207,142,000. BNP Paribas Financial Markets boosted its position in shares of BioNTech by 43.0% in the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after purchasing an additional 474,796 shares during the period. Bank of America Corp DE grew its stake in BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after buying an additional 166,432 shares during the last quarter. First Trust Advisors LP increased its position in BioNTech by 116.0% during the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after buying an additional 451,124 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new position in BioNTech during the second quarter worth approximately $39,385,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on BNTX. Sanford C. Bernstein reissued a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. Jefferies Financial Group restated a “buy” rating on shares of BioNTech in a research note on Monday, June 1st. UBS Group reaffirmed a “buy” rating on shares of BioNTech in a report on Wednesday, September 16th. Canaccord Genuity Group dropped their price target on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.